Lantern Pharma (LTRN) announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 Harmonic clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer, or NSCLC, who have progressed after receiving treatment with tyrosine kinase inhibitors, or TKIs.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio